Abstract
Thalidomide has been widely used in the treatment of various hematologic malignancies and inflammatory disorders. Here, we present a case of thalidomide induced anemia in a 65-year-old male patient diagnosed with multiple myeloma. This case underscores the importance of vigilance for hematological adverse effects in patients receiving thalidomide therapy and the need for close monitoring and prompt management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal For Multidisciplinary Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
